Hypoxia-induced pulmonary hypertension in adults and newborns: implications for drug development

•This review highlights some of the prominent mechanisms causing CHPH in adults and newborns, and emerging therapeutic targets of potential pharmaceuticals. Chronic hypoxia-induced pulmonary hypertension (CHPH) presents a complex challenge, characterized by escalating pulmonary vascular resistance a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug discovery today 2024-06, Vol.29 (6), p.104015-104015, Article 104015
Hauptverfasser: Ahmed, Abu Shufian Ishtiaq, Blood, Arlin B., Zhang, Lubo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•This review highlights some of the prominent mechanisms causing CHPH in adults and newborns, and emerging therapeutic targets of potential pharmaceuticals. Chronic hypoxia-induced pulmonary hypertension (CHPH) presents a complex challenge, characterized by escalating pulmonary vascular resistance and remodeling, threatening both newborns and adults with right heart failure. Despite advances in understanding the pathobiology of CHPH, its molecular intricacies remain elusive, particularly because of the multifaceted nature of arterial remodeling involving the adventitia, media, and intima. Cellular imbalance arises from hypoxia-induced mitochondrial disturbances and oxidative stress, reflecting the diversity in pulmonary hypertension (PH) pathology. In this review, we highlight prominent mechanisms causing CHPH in adults and newborns, and emerging therapeutic targets of potential pharmaceuticals.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2024.104015